Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL1442993 | 1.00 | TSHR (0.50) | TSHRATMATRALDH1A1HSD17B10 | |
| Methane SCHEMBL8628682 | 1.00 | — | — | |
| Methane SCHEMBL11037799 | 1.00 | TSHR (0.50) | TSHRATMATRALDH1A1HSD17B10 | |
| Methane SCHEMBL9769006 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 | |
| SCHEMBL7198648 | 0.94 | TSHR (0.56) | TSHRATMATRALDH1A1HSD17B10 | |
| SCHEMBL27509881 | 0.94 | — | — | |
| SCHEMBL8014988 | 0.94 | TSHR (0.56) | TSHRATMATRALDH1A1HSD17B10 | |
| SCHEMBL451238 | 0.94 | — | — | |
| Methane SCHEMBL8838996 | 0.94 | TSHR (0.56) | TSHRATMATRALDH1A1HSD17B10 | |
| Methane SCHEMBL11423626 | 0.94 | TSHR (0.56) | TSHRATMATRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200164341-A1 | METHOD OF MAKING A MERCURY SORBENT | AMCOL INTERNATIONAL CORP (US) | 2020-05-28 | — | — | US | claimed |
| US-20180304229-A1 | IMPROVED METHOD OF MAKING A MERCURY SORBENT | AMCOL INTERNATIONAL CORPORATION (US) | 2018-10-25 | — | — | US | claimed |
| EP-3368210-A1 | IMPROVED METHOD OF MAKING A MERCURY SORBENT | Amcol International Corporation (US) | 2018-09-05 | — | — | EP | claimed |
| EP-1259577-B1 | PROCESS FOR REMOVING MERCURY FROM HYDROCARBONS | UNION OIL CO (US) | 2007-03-21 | — | — | EP | claimed |
| US-20030116475-A1 | Process for removing mercury from liquid hydrocarbons using a sulfur-containing organic compound | FRANKIEWICZ THEODORE C (US) | 2003-06-26 | — | — | US | claimed |
| US-6537443-B1 | Removing colloids and treating with organic or inorganic sulfur containing compound such as an alkali or alkaline earth sulfide, dithiocarbamate or sulfurized isobutylene | UNION OIL COMPANY OF CALIFORNIA | 2003-03-25 | — | — | US | claimed |
| EP-1259577-A1 | PROCESS FOR REMOVING MERCURY FROM HYDROCARBONS | UNION OIL COMPANY OF CALIFORNIA (US) | 2002-11-27 | — | — | EP | claimed |
| WO-2001062870-A1 | PROCESS FOR REMOVING MERCURY FROM HYDROCARBONS | UNION OIL COMPANY OF CALIFORNIA (US) | 2001-08-30 | — | — | WO | claimed |
| EP-0972651-A1 | Image enhancing compositions | Xerox Corporation (US) | 2000-01-19 | — | — | EP | claimed |
| WO-1999034926-A1 | METHOD FOR RECOVERING AND SEPARATING METALS FROM WASTE STREAMS | KREISLER LAWRENCE (US) | 1999-07-15 | — | — | WO | claimed |
| US-5746814-A | Decurling compositions | XEROX CORPORATION (US) | 1998-05-05 | — | — | US | claimed |
| JP-58067874-A | — | — | None | — | — | JP | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| US-4324799-A | Fungicidal thioglycolic acid anilides, processes for their manufacture and pesticidal compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-04-13 | — | — | US | disclosed |
| US-4317758-A | SULFUR CONATING COMPOUNDS DISSOLVED IN A MODIFIED ACRYLAMIDE POLYMER | PHILLIPS PETROLEUM COMPANY (US) | 1982-03-02 | — | — | US | disclosed |
| EP-0039083-A1 | Viscosity-stabilized aqueous acrylamide polymer solutions and use of viscosity stabilizer compounds | PHILLIPS PETROLEUM COMPANY (US) | 1981-11-04 | — | — | EP | disclosed |
| US-4086339-A | OF N,N-DIMETHYL-DITHIOCARBAMATE AND 8-HYDROXY-QUINOLINE; FUNGICIDES, BACTERICIDES | ESZAKMAGYARORSZAGI VEGYIMUVEK (HU) | 1978-04-25 | — | — | US | disclosed |
| US-3962304-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | TSHR 4307/4885ATM 2664/4885ATR 2199/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | TSHR 2676/4885ATM 1963/4885ATR 1731/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | TSHR 3563/4885ATM 29/4885ATR 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.